The Global
Sleep Apnea Devices Market valued at $5.5 billion in 2021 and
is set to witness a CAGR of 7% by 2026. A large pool of
undiagnosed sleep apnea patients, a shift towards home-sleep testing, favorable
reimbursement of sleep apnea devices in key regions such as the US, rising
awareness about the ill-effects of untreated sleep apnea, availability of
funding or grants to revolutionize diagnosis & treatment for OSA, and foray
of a number of companies into the sleep apnea market are some of the key
factors driving the sleep apnea devices market growth. However, the lack of
patient compliance to treatment, especially CPAP therapy, is a key challenge
and is expected to impact the market’s growth.
Obstructive sleep apnea (OSA) is the most common form of
sleep-disordered breathing (SDB). It is a partial or complete collapse of the
upper airway caused by the relaxation of the muscles controlling the soft
palate and tongue. Globally nearly one billion adults aged 30 to 69 years are
estimated to have obstructive sleep apnea (OSA). The severity of sleep apnea is
measured by the frequency of apnea or hypopnea events per hour, which is
referred to as the Apnea-Hypopnea Index (AHI).
- Normal
Range: AHI < 5 events per hour
- Mild
Sleep Apnea: 5 ≤ AHI < 15 events per hour
- Moderate
Sleep Apnea: 15 ≤ AHI < 30 events per hour
- Severe
Sleep Apnea: AHI ≥ 30 events per hour
The prevalence of OSA has been increasing steadily, and as
per estimates, it affects ~3% to 20% of the general population.
Discover the more details-Download the PDF brochure:
https://meditechinsights.com/sleep-apnea-devices-market/request-sample/
Technological Advancements Drives the Sleep Apnea
Devices Market
The global sleep apnea devices market is a technology-driven
market and is marked by constant product enhancements and innovations. For
instance,
- In
October, 2021, AirAvant Medical introduced a new device called Bongo Rx
for the treatment of obstructive sleep apnea (OSA). The device is touted
as continuous positive airway pressure (CPAP) alternative and is
clinically proven to treat mild to moderate OSA symptoms. It is inserted
in the nostrils during sleep to create a seal to keep air flowing as the
sleeper breathes in and out.
- In
August 2021, Resmed, launched AirSense 11, the company’s next-generation
PAP (positive airway pressure) device. AirSense 11 includes new features
such as Personal Therapy Assistant and Care Check-In designed to provide
tailored guidance to PAP users, helping ease them into therapy and
comfortable nightly use. Other features include the availability of remote
software updates so that users can enjoy the latest version of these tools
every night.
- In
April, 2021, Somne, a digital health company, announced it is developing a
revolutionary non-invasive alternative to CPAP. The device is worn around
the neck and uses patented Variable Negative Pressure (UNEP) technology to
provide therapy to patients while they sleep.
Shift Towards Home Sleep Apnea Test (HSAT) Fuels the
Demand
The traditional way of sleep apnea testing required an
overnight stay at a sleep lab. Sensors that monitored bodily functions such as
heart, brain, muscle activity, and eye movements are placed on the chest, head,
near eyelids, and legs of patients. Nasal devices and chest/stomach bands are
also fitted to monitor and measure breathing patterns. Moreover, to monitor
patients’ overnight behavior, lab technicians also film the patient (with
permission) while being asleep. However, the trend is fast-changing now and
home sleep tests are now growing in popularity. A home sleep apnea test (HSAT)
is an overnight test that is conducted outside the hospital or sleep lab. These
tests are conducted using a special device that measures sleep patterns during
the night. HSATs cost less, generally require only a few monitors & straps,
and can take place in the comfort of a person’s home.
A home sleep apnea test (HSAT) is financially more
friendly. It costs ~ $200 to $600, which is relatively less than $800 to $3,000
for an overnight visit to a sleep lab. Also, insurers are increasingly
requiring HSAT as a first step before paying for an in-lab sleep apnea
test.” - Product Manager, Leading Sleep Apnea Diagnostic Device
Manufacturer, United States
Favorable Reimbursement of Sleep Apnea Devices in Key
Markets
The diagnosis and treatment of obstructive sleep apnea in
the US are covered when Medicare coverage criteria are met. Medicare Part B
(Medical Insurance) covers Type I, II, III, and IV sleep tests and
devices if you have clinical signs and symptoms of sleep apnea.
- In
the US, the diagnosis of OSA is covered. Examples of covered diagnostic
services include - Oximetry Testing, Polysomnography and Sleep Studies,
and Home Sleep Studies.
- The
treatment of OSA is also covered in the US. Examples of covered treatments
include - Continuous Positive Airway Pressure (CPAP), Respiratory Assist
Devices including Bilevel Positive Airway Pressure (BiPAP), Mandibular
Devices/Oral Appliances.
Organic and Inorganic Growth Strategies Adopted by
Players to Establish Their Foothold
The sleep apnea devices market is marked by the presence of
both established and new players. Players operating in the market adopt both
organic and inorganic growth strategies such as new product launches, and
partnerships to garner market share. For instance,
- In
December 2021, ZOLL® Medical Corporation, completed the acquisition of
Itamar™ Medical Ltd., a medical device and digital health company that
provides at-home testing for sleep apnea.
- In
February 2021, GoPAPfree, a homecare provider of oral appliance therapy
for obstructive sleep apnea launched a new oral appliance - O2Vent Optima.
The patented and exclusive appliance is the only device with integrated
airway technology and increases the response rate to sleep apnea therapy
by 40% as compared to standard mouthguards. Clinical trials also found it
to be the only device with a 100% response rate to snoring.
The sleep apnea devices market is a lucrative market that is
set to witness decent growth in the coming years due to technological
advancements in diagnostic and therapeutic sleep apnea devices, increasing
awareness campaigns & initiatives run by governments and manufacturers
across the globe, growing prominence & usage of oral appliances due to
their relative ease of use, portability, and newer innovations such as
compliance recorders that help in long-term follow-up and emerging technologies
that remotely adjust the appliance to optimize upper airway patency.
Unlock key
findings! Fill out a quick inquiry to access a sample report
https://meditechinsights.com/sleep-apnea-devices-market/request-sample/
Competitive Landscape Analysis: Sleep Apnea Devices
Market
The sleep apnea devices market is marked by the presence of
players such as ResMed, Philips Respironics, Fisher & Paykel Healthcare,
SomnoMed, Itamar Medical, Inspire Medical Systems, Compumedics, Oventus
Medical, Natus Medical, Drive DeVilbiss Healthcare, Whole You, BMC Medical,
among others.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment